Search

Your search keyword '"Bojinca, M."' showing total 114 results

Search Constraints

Start Over You searched for: Author "Bojinca, M." Remove constraint Author: "Bojinca, M."
114 results on '"Bojinca, M."'

Search Results

4. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

5. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis

6. BODY COMPOSITION CHANGES IN MEN WITH HIV/HCV COINFECTION, HIV MONOINFECTION, AND HCV MONOINFECTION

7. POS0569 LONG-TERM OUTCOMES OF CHILDREN BORN TO WOMEN WITH RHEUMATOID ARTHRITIS

8. POS1009 ASYMPTOMATIC ENTHESITIS AND DOMINANT SIDE RELATED PATTERNS IN SPONDYLOARTHRITIS – THE ROLE OF ULTRASONOGRAPHY IN EVERYDAY PRACTICE

9. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

12. FRI0551 PERFORMANCE OF THE 2019 AMERICAN COLLEGE OF RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM SYSTEMIC LUPUS ERYTHEMATOSUS CLASSIFICATION CRITERIA

15. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients

16. Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort

17. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

18. What have multicentre registries across the world taught us about the disease features of systemic sclerosis?

19. Test-retest reliability and correlations of 5 global measures addressing at-work productivity loss in patients with rheumatic diseases

20. Content validity of global measures for at-work productivity in patients with rheumatic diseases: An international qualitative study

21. What have multicentre registries across the world taught us about the disease features of systemic sclerosis?.

22. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy

23. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

28. FRI0428 Mean number of capillaries is associated with disease activity at 6 months follow-up in systemic sclerosis patients

31. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

32. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

33. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

39. SAT0681 Risk of active tuberculosis in patients with inflammatory arthritis receiving tnf-inhibitors

40. Extended thromboprophylaxis with betrixaban in acutely ill medical patients

41. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

45. THU0603 Performance of The 2013 American College of Rheumatology/european League against Rheumatism Systemic Sclerosis Classification Criteria

46. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

48. THU0331 Increased Incidence of Tuberculosis Among Systemic Lupus Erythematosus Patients – Should Tuberculosis Screening at Diagnosis be the Next Step?

49. AB1224-HPR Type of Personality – a New Item to Take into Account When Evaluating Quality of Life and Disease Activity in Rheumatoid Arthritis (RA) Patients

50. AB1052 Is the Quantitative Assessment of Power Doppler Continuous Loop Superior to Single Frame Evaluation in Msus?

Catalog

Books, media, physical & digital resources